Introduction
Allergic diseases result from an unbalanced response of the specific immune system, generating allergen-specific IgE antibodies, which mediate various clinical symptoms, such as immediate type hypersensitivity. The generation of allergen-specific IgE by B cells depends on the generation of IL-4-producing T helper (Th) type 2 cells. The existence of allergen-specific Th2 cells, however, is not sufficient for allergy pathogenesis, because these cells are also found in healthy individuals. In contrast, allergen-specific regulatory T cells (T regs ) occur at a higher frequency than their effector counterparts in healthy individuals [1 ] , and are capable of suppressing the proliferation and cytokine expression of Th1 and Th2 cells, and act on antigen-presenting cells (APC) [2 ] . T regs are defined on the basis of their function, in contrast to Th1 or Th2 cells, which are characterized by their gene products. The exact definition of the T reg phenotype is therefore often difficult. T regs include CD25 þ T regs expressing the FOXP3 transcription factor, which is considered a key factor necessary for the induction of T regs , similarly to the role of T-bet and GATA-3 in the commitment to Th1 and Th2 cells, respectively. The ectotrophic expression of FOXP3 is sufficient to induce a regulatory T-cell phenotype [3] , which is assumed to generate an anergic phenotype by the control of activatory transcription factors nuclear factor of activated T cells and nuclear factor kappa B [4, 5] . In addition to the CD25 þ T regs the IL-10-expressing (Tr1) cells and the transforming growth factor beta (TGF-b)-expressing T regs (Th3) were described [6, 7] . These T-cell phenotypes are overlapping and the suppressive action may be similar.
Different vaccination strategies alter the balance between effector and regulatory T-cell populations, which regulate peripheral tolerance. The specific immunotherapy is a high allergen dose vaccination strategy, which reprogrammes the peripheral tolerance against allergens. It is currently the only curative treatment of specific allergy. Whereas in classic specific immunotherapy the allergen is administered subcutaneously, sublingual immunotherapy (SLIT) takes advantage of mucosal lymphoid systems, which appear to facilitate tolerance induction. Different clinically relevant vaccination strategies were evaluated and have been reviewed [8] [9] [10] [11] . It was a great breakthrough in understanding the immunological background of immunotherapy, by demonstrating peripheral tolerance induction and the development of an anergic state in activated, specific T cells. In recent work it appeared that specific immunotherapy generates IL-10 or TGF-b-secreting regulatory T cells, which are capable of specifically suppressing an IgE-related immune response and to trigger IgG4 and IgA antibody production by B cells [12, 13] . A disadvantage of specific immunotherapy is the long-term duration of therapy along with the uncertainty as to whether tolerance will be achieved. The motivation to improve therapy, to facilitate tolerance induction and to find a predictive, diagnostic marker of successful specific immunotherapy is driving research on the cellular mechanisms of specific immunotherapy. Recent advances in the understanding of T regs and the new concepts on these mechanisms are discussed in the current review.
The therapeutic effects of specific immunotherapy may act on different phases, which reflect our current knowledge of the cellular and molecular mechanisms of vaccination. Therefore, the current review is structured along the lines of events, as they may appear during specific immunotherapy.
Early immunological events in specific immunotherapy
A recent study [14] revealed the fate of the lymphocytes after allergen injection by the transfer of radioactively labeled autologous leukocytes and revealed that inflammatory activity at the site of injection (aqueous depot extract) started within the first hour and subsequently increased in a time-dependent manner. Interestingly, SLIT did not induce axillary or intestinal, inflammatory radiolabeled spots, even though patients had swallowed the allergen extract. It is evident that specific immunotherapy and SLIT are different in their lymphoid pathways and that the inflammation and recruitment of distinct leukocytes starts immediately. The engagement of the innate immune system, along with specific antibodies is important in this early phase, in which allergen is encountered, taken up and modulation of the specific immune defence is facilitated. Noticeably, allergen exposure during specific immunotherapy does not trigger IgE-mediated positive feedback regulation, which would lead to more IL-4 secretion and more IgE synthesis. In contrast, high allergen doses during specific immunotherapy promote the engagement of the low-affinity FceRII (CD23), which is known as a negative feedback regulator of IgE-dependent responses [15] . The administered allergen in specific immunotherapy will not only be bound by specific IgE, but also by other immunoglobulin classes. IgG complexes with allergen are important in modulating the immune response and preventing IgEmediated reactions. An alternative immunoglobulin-independent strategy that interferes with APC functions involves the receptors for pathogen-associated molecular patterns, such as the Toll-like receptors (TLRs). It allows APCs to examine their environment for potentially dangerous pathogens and to carry this information to antigen-specific T cells, which convert this information into appropriate effector responses. Therefore, the activation of pathogenassociated molecular patterns could contribute to clinical outcome-specific immunotherapy, and thus represent an important target for vaccine adjuvants. However, the relationship between these receptors, DC maturation and T reg development, immune suppression and the turnover of T regs is not yet well understood. A recent study demonstrated that the suppressive function of T regs critically depends on immature DCs [22 ] , and is readily reversed by the maturation of DCs that are induced by granulocyte-macrophage colony-stimulating factor and do not require TLR activation. In contrast, the reversal of anergy by T regs was reported to depend on TLR activation of DCs. It involves the potentiation of T reg responsiveness to IL-2 by the cooperative effects of IL-1 and IL-6, which are both produced by TLR-activated, mature DCs [22 ] . Agonists for TLR-1 and TLR-4 were shown to decrease the allergic inflammation in experimental animal models, when given during sensitization [23] . The effect on T reg expansion, however, was not analysed in that study [23] . Taken together, TLRspecific adjuvants may promote T reg expansion, but do not provide decision signals preferentially to drive T reg differentiation over Th1/Th2 cells. Future studies may allow the design of adjuvants that facilitate T reg induction without interfering with preexisting regulatory networks, controlling pathogens and autoantigens that require T-cell activation or anergy.
Induction and maintenance of specific tolerance
Specific immunotherapy results in immunological allergen unresponsiveness, which may result in decreased or absent allergen-specific immediate hypersensitivity skinprick test responses, and reduced allergen-specific rhinitis or asthma symptoms, and in the case of insect venoms induce resistance to anaphylactic reactions. The immunological differences become apparent starting on days 3-7 [12, 24] . A key finding in the mechanisms of specific immunotherapy against bee venom allergy induced IL-10-dependent T-cell unresponsiveness (anergy) in vitro, 3-7 days after the initiation of specific immunotherapy and is fully developed after 28 days [12, 24, 25] . In addition, it was shown that IL-10-producing CD25 þ T regs increase after the initiation of specific immunotherapy [26] . In the case of insect ultra-rush vaccination, CD25 þ T cells reach maximal numbers in the periphery on day 15. The increase, however, starts as early as one day after therapy initiation [27] . There is evidence that FOXP3 expression increases between days 1 and 7 after the initiation of specific immunotherapy, which is accompanied by IL-10 and TGF-b expression in the same patients (G. Hofbauer, unpublished data). It is of great interest to understand the mechanisms of T reg induction in specific immunotherapy, because it may allow the therapeutic enhancement or facilitation of the induction of peripheral tolerance and thus the endogenous capacity of the organism to control allergen reactivity. Current knowledge from the early events of specific immunotherapy is not yet sufficient to link allergen control with the induction of T regs . However, the potential of tolerogenic APCs is evident as highlighted above. The antigen [28] and the absence of Th1 or Th2 driving conditions [29 ] is essential for the induction of T regs in vitro. It can thus can be hypothesized that the generation of T regs represents a default pathway that requires T-cell receptor activation as for any other T-cell differentiation, but the absence of decision signals for effector T cells [30 ] . This allows several observations to be integrated: T regs from cord blood, which are characterized by an uncommitted phenotype, also show a higher capacity for suppressive T reg function than T regs from adult donors [31] . TGF-b has been shown to promote FOXP3 expression [32] [33] [34] , but is also known to inhibit the Th1 driving transcription factor T-BET [35] and the Th2-driving transcription factor GATA-3 [36, 37] . We have demonstrated that glucocorticoids induce FOXP3 expression both in vivo and in vitro [29 ] . This study also shows that IL-10 promotes FOXP3 expression in vitro, but only if IL-4 and IL-12 were neutralized. Both cytokines represent 'decision' signals for T-cell differentiation, and induce the transcription factors GATA-3 or T-BET, respectively. The induction of FOXP3 by glucocorticoids was independent of IL-4/IL-12-neutralizing antibodies. However, it is known that glucocorticoids inhibit GATA-3 and T-BET expression, thus replacing neutralizing conditions or TGF-b for controlling the decision signals in the process of FOXP3 induction. The induction of T regs by the engagement of T-cell receptor and inhibitory receptors such as CD46 [38] , CD200R [39] , CTLA-4 [40] was demonstrated, and other inhibitory receptors may also have the capacity to regulate decision signals of T-cell differentiation negatively [41] .
Mechanism of suppression
The induction of specific immune suppression is a key step in the re-induction of peripheral tolerance and thus in specific immunotherapy. Several mechanisms have been reported to be involved in this process and represent potential targets for supportive vaccination strategies in specific immunotherapy. Generally, T reg -mediated suppression appeared to be antigen specific, which raised the question of how secreted cytokines could be involved in this process. However, recent findings showed that cytokines [42] and cytokine receptors [43 ,44] can become part of the immunological synapse, which is formed between the APCs and the T cells. Therefore, soluble cytokines can be shuttled in an antigen-specific manner to a neighboring cell and the neighboring cell can specifically receive signals. The suppression mediated by T regs renders the target cell into a non-responsive, non-apoptotic state (anergy). T-cell anergy can also be induced in vitro, when pure antigen-specific T cells are incubated with peptides in the absence of APCs [28, 45, 46] . Under these conditions, T cells possibly present the antigens themselves, but fail to costimulate each other, and therefore receive only one T-cell activation signal. For successful T-cell stimulation, two signals are necessary, whereas one signal alone results in T-cell anergy, which can be resolved by the addition of IL-2 [47] and IL-15 [48] . Therefore, T-cell anergy can be transient and anergized T cells are potentially available for later immune responses. Although the function of anergic cells as 'inactive memory' is speculative, it is interesting to note that peptide-induced T-cell anergy does not shut down the entire effector programme of T cells [28] . Increased IL-10 production [49] , IL-5 and IL-13 as well as the upregulation of IL-2R were reported (CD25; [28]). As anergized cells have similar phenotypes to T regs and target cells suppressed by T regs it appears possible that the mechanisms of suppression are related to the twosignal paradigm. T regs require IL-2 to mediate effective suppression [50, 51] , as anergic cells require IL-2 to become re-activated. An unbalanced activation of T cells by either signal one or two may cause suppression as was shown for costimulatory receptors such as CD28 [52, 53] , OX40 [54] , PD-1 [1 ,55] and 4C8 [56] . CTLA-4 is constitutively found on T regs , but its role in suppression is controversial as discussed [57] [58] [59] . The costimulatory receptors are capable of promoting phosphatidylinositol 3,4,5-trisphosphate phosphatase activity, which is a potent inhibitor of cell cycle progression [60] .
Interference with signal 1 may underlie tolerance induction by anti-CD4 monoclonal antibody or the MHCIIbinding receptor LAG-3 (CD223). Antibodies to CD223 inhibit suppression induced by T regs both in vitro and in vivo. Natural CD25 þ T regs express CD223 upon activation, which is significantly enhanced in the presence of effector cells, whereas CD25 þ T regs from CD223 knockout mice exhibit reduced regulatory activity [61 ] .
The suppressive cytokines such as IL-10 or TGF-b may interfere with the downstream signal of signal 1 or 2, by recruiting phosphatases to the signaling complexes [62, 63] , leaving only partial activation and thus programmes T-cell anergy.
Interestingly, genes involved in cytolysis (perforin, granzyme), were reported to be involved in T reg activity [64, 65] , suggesting that T regs or at least certain subsets of them may also induce cell death in target cells. In most experimental systems, however, cell death could be excluded as a mechanism underlying T reg -mediated suppression.
Maintenance of peripheral tolerance
The treatment success of specific immunotherapy is determined by stable tolerance against allergens. The current knowledge on the stability and turnover of T regs may help to maximize the efficacy of the maintenance vaccination of specific immunotherapy. The glucocorticoid-induced TNFR-related protein (GITR), which is preferentially expressed on the surface of T reg cells, provides a signal that abrogates T reg suppression. A soluble form of GITR ligand induces GITR-dependent nuclear factor kappa B activation and blocks in-vitro suppression mediated by both resting and pre-activated polyclonal and antigen-specific T regs [66] . The turnover or the suppressive capacity is not a constitutive parameter of T regs , and TGF-b was reported to play a role in the expansion of T regs in vivo. TGF-b may thus play a role in both T reg induction and the maintenance of suppression. Similar to activated effector T cells, T regs express the TGF-b RIII, endoglin, which may not only increase the affinity of T regs to TGF-b, but also allows T cells to proliferate in response to low amounts of TGF-b [67 ] . Moreover, TGF-b is a switch and promotion factor for B cells towards IgA isotype and thereby controls peripheral tolerance, particularily in food allergies [68] . Similar to TGF-b, IL-10 was reported to promote IgG4 and shifted IgG4/IgA levels towards normal conditions and the ratio of specific IgE to IgG4 or IgA changes approximately 100-1000-fold [6] . Unfortunately, recent studies could not establish birch pollen-specific IgG4 [69] nor IgA as a marker for successful specific immunotherapy [70] . Therefore, markers of T-cell responses, specifically for Molecules are attributed to three phases, a conditioning phase (a) preceding allergen-induced regulatory T-cell (T reg ) induction (b), and the phase of re-challenge and T regmediated suppression (c). The upper fields are factors counteracting, the lower fields factors that support T reg induction. APC, Antigen-presenting cell; GC, glucocorticoids; iDC, immature dendritic cell; GITR, glucocorticoid-induced TNFR-related protein; mDC, mature dendritic cell; SIT, specific immunotherapy; TGF-b, transforming growth factor beta; TLR, Toll-like receptor.
T reg induction and maintenance, may allow the direct monitoring of clinical success, which would greatly improve the treatment of allergies by specific immunotherapy.
Conclusion
The mechanisms of specific immunotherapy are characterized by an early induction of T regs , which are capable of controlling allergen-specific effector T cells. This process is supported by immature DCs (Fig. 1a) . As the effector T cells, particularly Th2 cells are necessary for IgE differentiation, it appears that the induction of sufficient numbers of T regs is crucial for the success of specific immunotherapy. Peripheral tolerance to allergen in the normal immune response of healthy individuals to allergen exposure and in specific immunotherapy is mainly the result of sufficient T reg numbers and not of the suppressive activity of T regs . It is hypothesized that T regs evolve when decision signals for Th1 or Th2 are absent (Fig. 1b) , as is the case in specific immunotherapy. Therefore, therapeutic development may aim to control the microenvironment, including the maturation of DCs or T reg induction before allergen exposure. The mechanism of suppression could not be defined by single receptors, but appears to involve an array of receptors (Fig. 1c) and can be categorized into two groups, those that are related to antigen-induced signaling and those to costimulatory signals. Research in the area of specific immunotherapy will take advantage of T reg -relevant genes, to identify early markers of clinical success and to develop T reg -focused vaccination strategies.
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